Increased Incidence of Precocious Puberty in Girls During COVID-19 Pandemic: Early Indicator of the Upcoming Childhood Metabolic Syndrome Pandemic?

To evaluate retrospectively the incidence of central precocious puberty (CPP) during the COVID 19 lockdown and comparing the data with the corresponding data from the previous 2 years. The study included 23 girls with CPP and 14 patients with early puberty. Nineteen patients were newly diagnosed with CPP compared to 4 patients diagnosed with CPP during the previous 2 years. The number of new patients diagnosed with CPP was significantly higher than the mean during the previous 2 years (P < .001). There were more overweight patients with CPP during and after the lockdown (P < .05). These patients had also increased uterus length (P < .05) and more advanced bone age (P < .05). The increase in the incidence of central precocious puberty during and after the lockdown due to COVID 19 can be considered a serious consequence of the increased fat mass and an early indicator of the worsening of childhood obesity.

Role of combining anticoagulant and antiplatelet agents in COVID-19 treatment: a rapid review.

Although primarily affecting the respiratory system, COVID-19 causes multiple organ damage. One of its grave consequences is a prothrombotic state that manifests as thrombotic, microthrombotic and thromboembolic events. Therefore, understanding the effect of antiplatelet and anticoagulation therapy in the context of COVID-19 treatment is important. The aim of this rapid review was to highlight the role of thrombosis in COVID-19 and to provide new insights on the use of antithrombotic therapy in its management. A rapid systematic review was performed using preferred reporting items for systematic reviews. Papers published in English on antithrombotic agent use and COVID-19 complications were eligible. Results showed that the use of anticoagulants increased survival and reduced thromboembolic events in patients. However, despite the use of anticoagulants, patients still suffered thrombotic events likely due to heparin resistance. Data on antiplatelet use in combination with anticoagulants in the setting of COVID-19 are quite scarce. Current side effects of anticoagulation therapy emphasise the need to update treatment guidelines. In this rapid review, we address a possible modulatory role of antiplatelet and anticoagulant combination against COVID-19 pathogenesis. This combination may be an effective form of adjuvant therapy against COVID-19 infection. However, further studies are needed to elucidate potential risks and benefits associated with this combination.